FCGR3A

Overview

FCGR3A (Fc Gamma Receptor IIIa), also known as CD16a, encodes a low-affinity cell surface receptor that binds to the Fc region of immunoglobulin G (IgG) antibodies. It is a member of the Fc gamma receptor (FcγR) family, a group of immunoreceptors that serve as a critical bridge between the humoral and cellular arms of the immune system. FcγRIIIa is predominantly expressed on natural killer (NK) cells, monocytes, macrophages, and dendritic cells, where it functions as a primary activating receptor mediating antibody-dependent cellular cytotoxicity (ADCC). Upon binding to IgG-opsonized target cells, FcγRIIIa triggers downstream signaling cascades that culminate in the degranulation of cytotoxic effectors and the secretion of pro-inflammatory cytokines such as IFNG (interferon-gamma) and IL18, enabling targeted elimination of infected, malignant, or otherwise aberrant cells.

The biological significance of FCGR3A extends well beyond innate immunity. A commonly studied single nucleotide polymorphism (SNP) in the gene, rs396991 (resulting in a valine-to-phenylalanine substitution at position 158 of the mature protein), is known to alter the receptor's binding affinity for IgG1 antibodies and has been extensively investigated as a pharmacogenomic determinant of response to therapeutic monoclonal antibodies, including rituximab. The receptor also serves as a critical quality-control target in the biopharmaceutical industry, where FcγRIIIa-binding assays are employed to characterize glycoform profiles and ADCC potency of antibody drug products. Its position at the intersection of innate immunity, therapeutic oncology, and antibody engineering makes FCGR3A one of the most clinically and pharmacologically relevant immune receptor genes in contemporary biomedical research.

Focus of Latest Publications

Recent publications highlight FCGR3A as a multifaceted research target spanning pharmacogenomics, biopharmaceutical quality assessment, protein engineering, NK cell immunotherapy, and neurological disease biomarker discovery.

Pharmacogenomics and rituximab Response in Glomerular Disease A 2026 study published in Pharmacology Research & Perspectives examined the impact of two Fc gamma receptor gene variants — FCGR2A (rs1801274) and FCGR3A (rs396991) — on the therapeutic efficacy of rituximab in patients with glomerular diseases. The FCGR3A rs396991 polymorphism, which alters receptor binding affinity for the Fc domain of IgG, has been hypothesized to modulate how effectively rituximab-opsonized B cells are recognized and cleared by FcγRIIIa-expressing effector cells. The study assessed clinical endpoints including biochemical parameters and rituximab concentration in a cohort of 30 patients receiving either 1.0 g or 0.5 g of rituximab. This work is part of a broader effort to understand why clinical responses to rituximab vary substantially between individuals, with FcγRIIIa polymorphism emerging as a candidate predictor alongside FCGR2A variants.

Biopharmaceutical Quality Assessment via 2D NMR A study published in mAbs (2026) evaluated two-dimensional nuclear magnetic resonance (2D NMR) spectroscopy as a tool for assessing structural consistency and functional relationships in monoclonal antibodies. FcγRIIIa binding and ADCC activity served as the functional readouts against which 2D NMR fingerprint changes were benchmarked. Using ECHOS correlation and principal component analysis, the authors demonstrated that subtle structural perturbations detectable by 2D NMR correlate with downstream changes in FcγRIIIa-mediated effector function. This positions FCGR3A-binding assays as a functional reference standard in antibody-dependent cellular cytotoxicity assessments during biopharmaceutical development.

Protein Engineering for Alkaline Stability A 2026 study in the Journal of Biochemistry investigated the mechanistic basis of alkaline instability in FcγRIIIa protein, specifically focusing on destabilization caused by tyrosine-tyrosine electrostatic repulsion under alkaline conditions. Using rational design approaches, the researchers explored phenylalanine substitution for L-tyrosine residues as a strategy to mitigate this instability, which is particularly relevant in the context of chromatographic clean-in-place (CIP) protocols used in antibody purification workflows. Because FcγRIIIa is widely used as an affinity ligand for glycoform analysis and antibody purification in industrial-scale biomanufacturing, its alkaline stability is of practical importance. Insights from alkaliphilic organisms informed the rational design strategy. This study advances understanding of structure-function relationships in FcγRIIIa beyond its immunological role and into its utility as a bioreagent.

NK Cell immunotherapy in Myeloid Leukemia Published in Blood Advances (2026), a study explored the use of exercise-mobilized lymphocytes to enhance cytokine-induced memory-like (CIML) NK cell function against myeloid leukemia. CD16 (encoded by FCGR3A) expression on NK cells was among the phenotypic markers assessed; exercise-activated NK cells (aNK-X) showed enriched CD16+ phenotypes alongside higher NKG2D+ and CD57+ expression and lower NKG2A expression compared to resting NK cells from the same donors. These aNK-X cells demonstrated stronger cytotoxicity against two myeloid leukemia cell lines, accompanied by enhanced IFNG production and degranulation. The data suggest that exercise-induced CD16 upregulation may partly underlie the augmented ADCC capacity of these cells, implicating FCGR3A expression levels as a functional correlate of NK cell anti-tumor potency.

Biomarker Discovery in Alzheimer's Disease and Postoperative Delirium A bioinformatics study published in Medicine (2026) identified FCGR3A as one of five hub genes representing common diagnostic biomarkers for both Alzheimer's disease (AD) and postoperative delirium (POD). The other hub genes included Bruton agammaglobulinemia tyrosine kinase (BTK), NCF2, CRH, and SERPINA3. The authors analyzed differentially expressed genes (DEGs) across multiple GEO datasets covering Alzheimer's disease and postoperative delirium samples, constructing protein-protein interaction (PPI) networks and applying machine learning to prioritize hub genes. The identification of FCGR3A — a canonical innate immune effector receptor — as a shared biomarker between these two neurological conditions supports growing evidence for neuroinflammatory mechanisms, potentially mediated through microglial or peripheral immune cell activity, as a common pathophysiological thread linking AD and POD.

Key Publications

Jun Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. (Pharmacology research & perspectives, 2026, PMID 42170767): "The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases."
May Common biomarkers of Alzheimer disease and postoperative delirium. (Medicine, 2026, PMID 42216384): "Five hub genes emerged as potential diagnostic biomarkers for both diseases, Bruton tyrosine kinase (BTK), NCF2, CRH, FCGR3A, and SERPINA3."
May 2D NMR assessment of structural consistency and functional relationships in monoclonal antibodies. (mAbs, 2026, PMID 42132213): "Changes in 2D NMR fingerprints were evaluated using ECHOS correlation and principal component analysis and compared with FcγRIIIa binding and ADCC activity."
May Mitigating alkaline instability induced by tyrosine-tyrosine repulsion in an FcγRIIIa-binding protein through phenylalanine substitution. (Journal of biochemistry, 2026, PMID 41823110): "In this study, we investigated alkaline stability mechanisms in Fc gamma receptor IIIa, a critical immune effector protein with applications in antibody purification and glycoform analysis."
Apr Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia. (Blood advances, 2026, PMID 41538301): "aNK-X cells exhibited stronger cytotoxicity against 2 myeloid leukemia cell lines than aNK cells from the same donors, accompanied by increased interferon gamma production, enhanced degranulation, and an enriched phenotype (higher NKG2A-/NKG2D+, CD57+, CD16+)."